Organovo Holdings, Inc. (ONVO) Bundle
Understanding Organovo Holdings, Inc. (ONVO) Revenue Streams
Understanding Organovo Holdings, Inc.’s Revenue Streams
Primary Revenue Sources
- Royalty Revenue: $53,000 for the six months ended September 30, 2024, a decrease of 29% from $75,000 in the same period of 2023.
- Product Revenue: $16,000 for the six months ended September 30, 2024, compared to $0 in the prior year, marking a 100% increase.
Year-over-Year Revenue Growth Rate
| Period | Total Revenue | Year-Over-Year Change |
|---|---|---|
| Six Months Ended September 30, 2024 | $69,000 | -8% (from $75,000 in 2023) |
| Three Months Ended September 30, 2024 | $30,000 | New revenue stream initiated |
Contribution of Different Business Segments to Overall Revenue
| Segment | Revenue (6 Months Ended September 30, 2024) | Percentage of Total Revenue |
|---|---|---|
| Royalty Revenue | $53,000 | 76.8% |
| Product Revenue | $16,000 | 23.2% |
Analysis of Significant Changes in Revenue Streams
The transition to product revenue is notable, with the first sales reported in 2024, showing a shift in revenue strategy. The decline in royalty revenue indicates potential challenges in the licensing agreements, particularly a decrease in sales by the licensee.
Overall, the company reported total revenues of $69,000 for the six months ended September 30, 2024, down from $75,000 in the same period of 2023, reflecting a 8% decrease year-over-year. This trend highlights the need for strategic adjustments to enhance revenue growth moving forward.
A Deep Dive into Organovo Holdings, Inc. (ONVO) Profitability
A Deep Dive into Organovo Holdings, Inc. Profitability
Gross Profit Margin: For the six months ended September 30, 2024, total revenues were $69,000, with a cost of revenues of $3,000. This results in a gross profit of $66,000, leading to a gross profit margin of approximately 95.65%.
Operating Profit Margin: The loss from operations for the same period was $5.994 million. Given total revenues of $69,000, the operating profit margin is calculated as -8,670%.
Net Profit Margin: The net loss for the six months ended September 30, 2024, was $5.893 million. Therefore, the net profit margin is -8,550% based on total revenues of $69,000.
Trends in Profitability Over Time
Comparing the six months ended September 30, 2024, to the same period in 2023, the company reported a decrease in total revenues from $75,000 in 2023 to $69,000 in 2024, a decline of 8%.
The net loss increased from $8.022 million in 2023 to $5.893 million in 2024, reflecting a narrowing of losses by approximately 26%.
| Metric | Six Months Ended September 30, 2024 | Six Months Ended September 30, 2023 | Change (%) |
|---|---|---|---|
| Total Revenue | $69,000 | $75,000 | -8% |
| Net Loss | $(5,893,000) | $(8,022,000) | 26% |
Comparison of Profitability Ratios with Industry Averages
As of the latest financial data, the company's gross profit margin of 95.65% is significantly higher than the industry average of approximately 60%. However, the operating and net profit margins are substantially lower than the industry average of around 10% and 5%, respectively.
Analysis of Operational Efficiency
The cost of revenues for the six months ended September 30, 2024 was $3,000, representing a 4.35% of total revenues, indicating strong cost management strategies in place. Research and development expenses totaled $2.386 million, a decrease of 20% from the previous year, reflecting improved operational efficiency.
Selling, general and administrative expenses also saw a reduction from $5.384 million in 2023 to $3.674 million in 2024, marking a 32% decline in spending, which contributes positively to the overall profitability metrics.
| Expense Type | Six Months Ended September 30, 2024 | Six Months Ended September 30, 2023 | Change (%) |
|---|---|---|---|
| Cost of Revenues | $3,000 | $0 | N/A |
| Research & Development Expenses | $2,386,000 | $3,001,000 | -20% |
| Selling, General & Administrative Expenses | $3,674,000 | $5,384,000 | -32% |
Debt vs. Equity: How Organovo Holdings, Inc. (ONVO) Finances Its Growth
Debt vs. Equity: How Organovo Holdings, Inc. Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, the total liabilities of Organovo Holdings, Inc. amounted to approximately $3.1 million, which includes both current and non-current liabilities. The breakdown is as follows:
| Type of Liability | Amount (in thousands) |
|---|---|
| Current Liabilities | $2,414 |
| Non-Current Liabilities | $660 |
| Total Liabilities | $3,074 |
Current liabilities include accounts payable of $419,000, accrued expenses of $879,000, insurance premium financing liability of $385,000, and operating lease liabilities.
Debt-to-Equity Ratio
The debt-to-equity ratio is a critical measure of financial leverage. As of September 30, 2024, Organovo's total stockholders' equity was approximately $3.7 million. The debt-to-equity ratio can be calculated as follows:
| Metric | Value |
|---|---|
| Total Liabilities | $3,074,000 |
| Total Stockholders' Equity | $3,680,000 |
| Debt-to-Equity Ratio | 0.84 |
This ratio indicates a balanced approach to financing, with a moderate level of debt relative to equity, which is favorable compared to the industry average of around 1.0.
Recent Debt Issuances and Credit Ratings
In September 2024, the company entered into an insurance premium financing agreement for $400,000 with an annual interest rate of 8.57% and a term of nine months. The company made a down payment of 10% and is required to make monthly payments of $44,281.
As of the latest reports, Organovo does not hold any formal credit rating from major agencies, reflecting its status as a smaller firm in the biotechnology sector.
Balancing Debt Financing and Equity Funding
Organovo has primarily financed its operations through equity financing, raising approximately $5.9 million through common stock sales in the six months ended September 30, 2024. The company has utilized an at-the-market (ATM) sales program and conducted a public offering in May 2024, generating net proceeds of $4.5 million.
This reliance on equity funding is complemented by the company's modest use of debt, allowing it to maintain flexibility while minimizing interest obligations. The mix of debt and equity aids in sustaining growth without over-leveraging the company's balance sheet.
Assessing Organovo Holdings, Inc. (ONVO) Liquidity
Assessing Organovo Holdings, Inc. Liquidity
As of September 30, 2024, the company reported total current assets of approximately $4.8 million and current liabilities of approximately $2.4 million, resulting in working capital of $2.4 million. This is an increase from March 31, 2024, when total current assets were approximately $3.9 million and current liabilities were approximately $1.9 million, leading to working capital of $2.0 million.
| Period | Total Current Assets | Total Current Liabilities | Working Capital |
|---|---|---|---|
| September 30, 2024 | $4.8 million | $2.4 million | $2.4 million |
| March 31, 2024 | $3.9 million | $1.9 million | $2.0 million |
Current and Quick Ratios
Based on the current assets and liabilities, the current ratio can be calculated as follows: Current Ratio = Current Assets / Current Liabilities = 2.00 as of September 30, 2024. The quick ratio, which excludes inventory from current assets, is calculated as follows: Quick Ratio = (Current Assets - Inventory) / Current Liabilities. With inventory at approximately $640,000 as of September 30, 2024, the quick ratio is 1.86.
Cash Flow Statements Overview
For the six months ended September 30, 2024, the cash flow statements indicated the following:
| Cash Flow Type | Six Months Ended September 30, 2024 | Six Months Ended September 30, 2023 |
|---|---|---|
| Operating Activities | $(5,625,000) | $(8,460,000) |
| Investing Activities | $20,000 | $776,000 |
| Financing Activities | $5,878,000 | $0 |
| Net Increase (Decrease) in Cash | $273,000 | $(7,684,000) |
During the six months ended September 30, 2024, the company reported a net cash used in operating activities of approximately $5.6 million, a decrease from $8.5 million in the prior year. This reduction can be attributed primarily to a $2.0 million cash payment for acquired in-process research and development assets.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company had cash and cash equivalents of approximately $3.2 million and restricted cash of approximately $0.1 million. The accumulated deficit stood at approximately $345.6 million. The company has financed its operations primarily through the sale of common stock and has raised approximately $5.9 million from financing activities during this period.
Despite the recent capital raises, the company has indicated substantial doubt about its ability to continue as a going concern for at least one year following the issuance of its financial statements, primarily due to ongoing liquidity risks. The negative cash flows from operations and the reliance on financing through equity sales highlight potential liquidity concerns moving forward.
Is Organovo Holdings, Inc. (ONVO) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the valuation metrics for the company are as follows:
- Price-to-Earnings (P/E) Ratio: Not applicable due to net losses.
- Price-to-Book (P/B) Ratio: Calculated as Market Price per Share / Book Value per Share. As of September 30, 2024, the book value per share was approximately $0.24.
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Not applicable due to negative EBITDA.
The current stock price trends have shown volatility over the last 12 months. The stock price has fluctuated significantly, with a 52-week range of approximately $0.30 to $1.00.
| Metric | Value |
|---|---|
| Market Price per Share | $0.64 |
| Book Value per Share | $0.24 |
| P/B Ratio | 2.67 |
| Current Assets | $4.8 million |
| Current Liabilities | $2.4 million |
| Working Capital | $2.4 million |
| Net Loss (6 months ended Sept 30, 2024) | $5.89 million |
| Net Cash Used in Operating Activities | $5.63 million |
The company does not currently pay dividends, which is reflected in a dividend yield of 0%.
Analyst consensus on the stock valuation varies, with some analysts rating it as a hold, while others suggest a cautious approach due to ongoing financial losses and liquidity concerns. The consensus rating is mixed, with a few analysts recommending to buy based on potential future growth opportunities.
Overall, the company is currently facing challenges in profitability and liquidity, raising questions about its valuation and potential for future growth.
Key Risks Facing Organovo Holdings, Inc. (ONVO)
Key Risks Facing Organovo Holdings, Inc.
Organovo Holdings, Inc. faces several internal and external risks that significantly impact its financial health. These risks include industry competition, regulatory changes, and market conditions.
Industry Competition
Organovo operates in the highly competitive biotechnology sector. The company is competing against established biotechnology firms and emerging startups that are also developing advanced tissue engineering technologies. This intense competition may hinder Organovo's ability to capture market share and achieve profitability.
Regulatory Changes
The biotechnology industry is heavily regulated, and any changes in regulations can impact operational capabilities. For instance, obtaining regulatory approvals for new products is a lengthy and uncertain process. The company must comply with various regulatory standards set by the FDA and other international bodies, which can delay product launches and increase costs.
Market Conditions
Market conditions can have a direct effect on Organovo's financial performance. Economic downturns can lead to reduced spending on research and development by pharmaceutical companies, which could impact demand for Organovo's products and services. Furthermore, fluctuations in the stock market may affect the company's ability to raise capital.
Operational Risks
Operational risks include challenges in scaling production and maintaining quality control in tissue engineering processes. Any failures in operational efficiency could lead to increased costs and hinder the company's growth prospects.
Financial Risks
As of September 30, 2024, Organovo reported total current assets of approximately $4.8 million and current liabilities of approximately $2.4 million, resulting in working capital of $2.4 million . The company has incurred significant operating losses, totaling $5.9 million for the six months ended September 30, 2024 . As of the same date, the accumulated deficit reached approximately $345.6 million . The company has also raised $5.9 million through financing activities during this period .
Strategic Risks
The company's growth strategy relies on successful collaborations and licensing agreements with pharmaceutical companies. Any failure to secure such partnerships could adversely affect its ability to fund research and development initiatives. Additionally, the company has indicated that it will need substantial additional funding to support future operating activities .
Mitigation Strategies
To mitigate these risks, Organovo has engaged in various strategies, including securing additional financing through public offerings and at-the-market (ATM) sales. In May 2024, the company conducted a public offering, raising approximately $4.5 million . Furthermore, it is actively pursuing collaborations with pharmaceutical companies to enhance its research capabilities and product offerings.
| Risk Factor | Description | Impact |
|---|---|---|
| Industry Competition | Competition from other biotech firms | Potential loss of market share |
| Regulatory Changes | Changes in FDA regulations | Delays in product launches |
| Market Conditions | Economic downturns affecting R&D spending | Reduced demand for products |
| Operational Risks | Challenges in production scaling | Increased costs |
| Financial Risks | High accumulated deficit and operating losses | Liquidity concerns |
| Strategic Risks | Failure to secure collaborations | Impact on R&D funding |
Future Growth Prospects for Organovo Holdings, Inc. (ONVO)
Future Growth Prospects for Organovo Holdings, Inc.
Analysis of Key Growth Drivers
The company has identified several key growth drivers that may enhance its market position:
- Product Innovations: The introduction of human cell-based products through the Mosaic division has started generating revenue, with product revenue reaching $16,000 for the six months ended September 30, 2024.
- Market Expansions: The company plans to expand its market reach by entering into collaborations with pharmaceutical companies to develop and commercialize new therapies.
- Acquisitions: Future acquisitions may play a role in diversifying product offerings and enhancing technological capabilities.
Future Revenue Growth Projections and Earnings Estimates
Revenue projections indicate a potential increase in sales as the company scales its production capabilities. The expectation is that quarterly product revenue will continue to grow following the initial sales. Current estimates suggest a total operating expense for the fiscal year ending March 31, 2025, to be between $13 million and $15 million.
Strategic Initiatives or Partnerships That May Drive Future Growth
Strategic initiatives include:
- Collaboration agreements with leading pharmaceutical companies for drug development.
- Participation in industry partnerships focused on advancing regenerative medicine.
Competitive Advantages That Position the Company for Growth
The company possesses several competitive advantages:
- Intellectual Property: A robust portfolio of patents related to its human cell technology.
- First-Mover Advantage: Being among the pioneers in the 3D bioprinting of human tissues positions it uniquely in the market.
- Established Relationships: Existing relationships with academic institutions and research organizations enhance its credibility and access to resources.
Financial Overview and Recent Performance
The financial performance for the six months ended September 30, 2024, is summarized as follows:
| Metric | September 30, 2024 | September 30, 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Royalty Revenue | $53,000 | $75,000 | ($22,000) | (29%) |
| Product Revenue | $16,000 | $0 | $16,000 | 100% |
| Total Revenue | $69,000 | $75,000 | ($6,000) | (8%) |
| Net Loss | ($5,893,000) | ($8,022,000) | $2,129,000 | 26% |
As of September 30, 2024, total current assets were approximately $4.8 million, while current liabilities stood at approximately $2.4 million, resulting in working capital of $2.4 million.
Organovo Holdings, Inc. (ONVO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Organovo Holdings, Inc. (ONVO) Financial Statements – Access the full quarterly financial statements for Q2 2024 to get an in-depth view of Organovo Holdings, Inc. (ONVO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Organovo Holdings, Inc. (ONVO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.